

ASX Announcement (ASX: HLS)

ASX Limited
Market Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000



HEALIUS LIMITED
ACN 064 530 516
REGISTERED OFFICE:
LEVEL 6
203 PACIFIC HIGHWAY
ST LEONARDS NSW 2065
TEL: +61 2 9432 9400
FAX: +61 2 9432 9447

9 December 2020

Healius announces on-market share buy-back

Healius Limited (ASX: HLS) today announces that the Board has approved the proposal to conduct an on-market share buy-back of up to \$200 million over the next 12 months in accordance with the terms specified in the **attached** Appendix 3C.

The buy-back will be managed within the '10/12 limit' permitted by the *Corporations Act*, and therefore does not require shareholder approval.

Healius intends to conduct the buy-back having regard to the prevailing share price, market conditions, any incremental capital requirements and unforeseen circumstances.

It is Healius' intention to commence the on-market buy-back in late December 2020, before pausing on 1 January 2021 when the Company enters its blackout period until its 1H FY21 results announcement on 24 February 2021, after which it intends to resume the buy-back.

Healius is holding an investor briefing at 10.30am AEDT today (refer to following page for webcast details) and an investor update has been lodged with the ASX separately today.

ENDS

Authorised by the Company Secretary.

For further information contact:

Janet Payne
Group Executive, Corporate Affairs
Mobile: +61 409 995 517

Charlene Jaw
Manager, Corporate Affairs
Mobile: +61 403 222 810

For over 30 years Healius has been one of Australia's leading healthcare companies with a commitment to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has three businesses, pathology, imaging and day hospitals/IVF. Through its unique footprint of centres and its 10,500 employees, Healius provides specialty diagnostic services to consumers and their referring practitioners, as well as well as enabling independent healthcare professionals to deliver care in its day hospitals and fertility clinics.

Investor Briefing details:

Webcast details are as follows:

Date: **Wednesday 9 December 2020**

Time: **10:30am (AEDT)**

Webcast link: <https://webcast.openbriefing.com/6923/>

There will be an opportunity to ask written questions via the webcast terminal via the "Submit a question" button on the bottom right of the webcast terminal.

If you would like to dial-in via teleconference or ask a question on the phone, please pre-register using this link and you will receive dial-in details and a unique access PIN:

<https://s1.c-conf.com/diamondpass/10011345-fLnl6e.html>

To ask a question during the Q&A session, participants will need to dial "*"1" (star, 1) on their telephone pad. To cancel your question, participants will need to dial "#" (hash) on their telephone pad. For help during the teleconference, participants will need to dial "*0" (star, 0) on their telephone pad.

Appendix 3C

Announcement of buy-back (except minimum holding buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

Name of entity	ABN/ARSN
HEALIUS LIMITED	24 064 530 516

We (the entity) give ASX the following information.

Information about buy-back

1	Type of buy-back	On-market (within 10/12 limit).
2	⁺ Class of shares/units which is the subject of the buy-back (eg, ordinary/preference)	Ordinary shares.
3	Voting rights (eg, one for one)	One for one.
4	Fully paid/partly paid (and if partly paid, details of how much has been paid and how much is outstanding)	Fully paid ordinary shares.
5	Number of shares/units in the ⁺ class on issue	623,008,113
6	Whether shareholder/unitholder approval is required for buy-back	No (within 10/12 limit).
7	Reason for buy-back	Capital management.

⁺ See chapter 19 for defined terms.

8	Any other information material to a shareholder's/unitholder's decision whether to accept the offer (eg, details of any proposed takeover bid)	Nil.
---	------------------------------------------------------------------------------------------------------------------------------------------------	------

On-market buy-back

9	Name of broker who will act on the company's behalf	UBS AG, Australia Branch.
10	Deleted 30/9/2001.	N/A
11	If the company/trust intends to buy back a maximum number of shares - that number Note: This requires a figure to be included, not a percentage.	The number of shares for which the aggregate buy-back consideration paid or payable is up to AUD\$200 million.
12	If the company/trust intends to buy back shares/units within a period of time - that period of time; if the company/trust intends that the buy-back be of unlimited duration - that intention	12 month duration – from 29 December 2020 to 28 December 2021. <i>(subject to the earlier completion of the buy-back and the Company exercising its right to suspend or terminate the buy-back or amend its terms, at any time)</i>
13	If the company/trust intends to buy back shares/units if conditions are met - those conditions	N/A

Employee share scheme buy-back

14	Number of shares proposed to be bought back	N/A
15	Price to be offered for shares	N/A

Selective buy-back

- 16 Name of person or description of class of person whose shares are proposed to be bought back N/A
- 17 Number of shares proposed to be bought back N/A
- 18 Price to be offered for shares N/A

Equal access scheme


- 19 Percentage of shares proposed to be bought back N/A
- 20 Total number of shares proposed to be bought back if all offers are accepted N/A
- 21 Price to be offered for shares N/A
- 22 ⁺Record date for participation in offer N/A
Cross reference: Appendix 7A, clause 9.

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:  Date: 9 December 2020
Company Secretary

Print name: Charles Tilley

⁺ See chapter 19 for defined terms.